AU4388993A - Treatment of cellular hyperproliferation by inhibition of interleukin-1 - Google Patents

Treatment of cellular hyperproliferation by inhibition of interleukin-1

Info

Publication number
AU4388993A
AU4388993A AU43889/93A AU4388993A AU4388993A AU 4388993 A AU4388993 A AU 4388993A AU 43889/93 A AU43889/93 A AU 43889/93A AU 4388993 A AU4388993 A AU 4388993A AU 4388993 A AU4388993 A AU 4388993A
Authority
AU
Australia
Prior art keywords
oligomer
interleukin
cytokine
cells
target gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU43889/93A
Other languages
English (en)
Inventor
Kevin D Cooper
Craig Hammerberg
Kameron W. Maxwell
Ben Y Tseng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genta Inc
University of Michigan
Original Assignee
Genta Inc
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genta Inc, University of Michigan filed Critical Genta Inc
Publication of AU4388993A publication Critical patent/AU4388993A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU43889/93A 1992-05-22 1993-05-21 Treatment of cellular hyperproliferation by inhibition of interleukin-1 Abandoned AU4388993A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88773492A 1992-05-22 1992-05-22
US887734 1992-05-22

Publications (1)

Publication Number Publication Date
AU4388993A true AU4388993A (en) 1993-12-30

Family

ID=25391751

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43889/93A Abandoned AU4388993A (en) 1992-05-22 1993-05-21 Treatment of cellular hyperproliferation by inhibition of interleukin-1

Country Status (9)

Country Link
EP (1) EP0644765A4 (es)
JP (1) JPH07508977A (es)
KR (1) KR950701528A (es)
AU (1) AU4388993A (es)
CA (1) CA2136349A1 (es)
IL (1) IL105741A0 (es)
MX (1) MX9302951A (es)
NZ (1) NZ253509A (es)
WO (1) WO1993024134A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
GB9405021D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
ATE428785T1 (de) 1996-03-01 2009-05-15 Euroscreen Sa Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
IL133913A0 (en) * 1997-07-10 2001-04-30 Therakos Inc Treatment of inflammatory disorders of the bowel and urinary bladder
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
US7960355B2 (en) 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
WO2006084145A2 (en) * 2005-02-02 2006-08-10 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to reduce c-reactive protein
GB0607189D0 (en) * 2006-04-10 2006-05-17 Polybiomed Ltd interleukin IL 1ra composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0353290A4 (en) * 1988-01-21 1990-09-05 Chemex Pharmaceuticals, Inc. Selective inhibition of gene expression by photoactivatable oligonucleotides
EP0527790A4 (en) * 1990-04-09 1993-09-15 The American National Red Cross Rejuvenation compositions and methods for their use
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
IL101978A0 (en) * 1991-05-31 1992-12-30 Genta Inc Neutral oligomers capable of being delivered transdermally and across mucous membranes
HU220098B (hu) * 1991-08-30 2001-10-28 Vertex Pharmaceuticals Incorporated Interleukin-1 béta proteáz enzim, és interleukin-1 béta proteáz inhibitorok

Also Published As

Publication number Publication date
EP0644765A4 (en) 1997-02-26
MX9302951A (es) 1994-07-29
KR950701528A (ko) 1995-04-28
EP0644765A1 (en) 1995-03-29
WO1993024134A1 (en) 1993-12-09
NZ253509A (en) 1999-09-29
JPH07508977A (ja) 1995-10-05
IL105741A0 (en) 1993-09-22
CA2136349A1 (en) 1993-12-09

Similar Documents

Publication Publication Date Title
Tang et al. Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity
JP3600831B2 (ja) トランスフォーミング成長因子−β（ＴＧＦ‐β）の免疫抑制効果の治療用アンチセンス−オリゴヌクレオチド類
EP0736093B1 (en) ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB-2 PLAYS A ROLL
US6005094A (en) Oligonucleotide analogues having improved stability at acid pH
CA2152672A1 (en) Oligomers having improved stability at acid ph
EP0644765A1 (en) Treatment of cellular hyperproliferation by inhibition of interleukin-1
JPH10508760A (ja) ｒａｆ遺伝子発現のアンチセンスオリゴヌクレオチド調節
JPH10510700A (ja) アンチセンスオリゴヌクレオチドを用いてカポジ肉腫を治療する方法
JPH09507502A (ja) ｒａｆ遺伝子発現のアンチセンスオリゴヌクレオチド調節
WO2001048190A2 (en) Therapeutic uses of lna-modified oligonucleotides
EP1141278B1 (en) Therapeutic pde4d phosphodiesterase inhibitors
WO2000071703A2 (en) Inhibition of histone deacetylase
JP2003505080A (ja) ヒトｅｇ５の発現を阻害するためのオリゴヌクレオチド
JP2002523335A (ja) Ｖｅｇｆ発現の抑制のためのアンチセンスオリゴヌクレオチド
WO2023041079A1 (zh) Lpa抑制剂及其用途
EP0747386A2 (en) Method and antisense oligonucleotides to Interleukin-6 receptor mRNA for inhibiting cellular proliferation
KR102304280B1 (ko) 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드
US5716846A (en) Method for inhibiting cellular proliferation using antisense oligonucleotides to interleukin-6 receptor mRNA
US10894962B2 (en) Carboxylated 2′-amino-LNA nucleotides and oligonucleotides comprising the same
CN114369130B (zh) 修饰的硫代寡核苷酸及其应用
EP0747480A1 (en) Oligonucleotides specific for cytokine signal transducer gp130 mRNA
Shinozuka et al. Novel DNA Analog for Potential Gene Regulating Agent. A Convenient Synthesis of. ALPHA.-Oligodeoxyribonucleotide Phosphorothioate Bearing 3'-Monophosphate.
US20040242519A1 (en) Antisense oligonucleotides for treatment of proliferating cells
Meng Synthesis and binding of oligonucleotides containing 2'-modified sulfide-or sulfone-linked dimers
MXPA01000910A (es) Oligonucleotidos antisentido para la exhibicion de expresion de vegf